Victor Chen, MD, MPH

Areas of Focus: 
Benign and Malignant Brain Tumors, including Stereotactic Radiosurgery (Gamma Knife)
Lung Cancer
Prostate Cancer
Stereotactic Body Radiation Therapy (SBRT)
Breast Cancer

About Me

I am a firm believer in patient-centered care, and I am strongly committed to providing state-of-the-art, evidence-based treatment for every patient. My goal as a radiation oncologist is to empower the patient and their loved ones in the decision-making process, so that I can provide compassionate care that is tailored to each patient's individual needs.

- Victor Chen, MD, MPH

Dr. Chen chose to specialize in radiation oncology because he enjoys the collaborative nature of the specialty – he not only gets to work with nurses, radiation therapists, dosimetrists, and physicists on a daily basis within the radiation oncology department, but he also works with physicians across many different specialties (such as medical oncology, surgical oncology, neurosurgery, and urology to name a few) in order to develop the optimal multidisciplinary treatment plan for each patient. In addition, Dr. Chen enjoys the personal relationship that a radiation oncologist gets to develop with each individual patient and their loved ones throughout each patient's treatment course. 

Concurrently with his residency training, Dr. Chen completed a Master of Public Health (MPH) degree, which allowed him to gain an appreciation of aspects of healthcare that are not commonly taught during medical school, such as cost-effectiveness, health equity, and social determinants of health. His MPH training provides him with a more holistic approach to cancer care, which Dr. Chen believes will be essential in the rapidly evolving US healthcare landscape. 

Dr. Chen most enjoys the personal relationships that he develops with every patient. He particularly enjoys working closely with each patient to develop treatment goals and share with them the good news (at the end of a treatment course, or during follow-up visits) about the success of a radiation treatment – whether that means that they are cancer-free, or that their quality of life has been greatly improved, for example. 



Other Interests: 

As an avid hiker, Dr. Chen enjoys the wide variety of outdoor recreational opportunities that are available both within the Portland metro area or just a short drive away. He also likes exploring all the great restaurants in town (particularly the Asian restaurants) as well as the wineries in the Portland area. The vibrant, quirky culture of Portland is also a big reason why he enjoys living in the area. Outside of work, Dr. Chen enjoys hiking, exploring new restaurants, cooking, and traveling. 


My Work

Hospitals Served: 
Providence Portland Medical Center
Providence St. Vincent Medical Center
Areas of Focus: 
Benign and Malignant Brain Tumors, including Stereotactic Radiosurgery (Gamma Knife)
Lung Cancer
Prostate Cancer
Stereotactic Body Radiation Therapy (SBRT)
Breast Cancer

Education & Honors

Board Certification: 
Radiation Oncology - Board Eligible
Education & Training: 
  • Residency, Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, 2022
  • MPH, Thomas Jefferson University, Philadelphia, PA, 2021 ​
  • Internship, Department of General Surgery, Harbor-UCLA Medical Center, Torrance, CA, 2018
  • MD, University of California, San Diego School of Medicine, La Jolla, CA, 2017​
  • BS, California Institute of Technology, Pasadena, CA, 2013​
  • Chen VE, Lombardo JF, Castaneda SA, Winkfield KM, Fisher SA, Gressen EL, Rudoler SB, Yan W, Gajjar SR. “Disparities in lung cancer for Black patients in the US: An overview of contributing factors and potential strategies for radiation oncologists to bridge the gap.” Applied Radiation Oncology. 2020 Dec;9(4): 16-20.
  • Ali AS, Chen VE, Zurlo C, Taylor JM, Fernandez C, Shi W. “Target treatment with stereotactic radiation for recurrent gliomas.” Chinese Clinical Oncology. 2020 Dec;9(6): 74. doi: 10.21037/cco.2020.03.05
  • Taylor JM, Chen VE, Miller RC, Greenberger BA. “The impact of prostate cancer treatment on quality of life: a narrative review with a focus on randomized data.” Research and Reports in Urology. 2020 Oct;12: 533-546. doi: 10.2147/RRU.S243088
  • Chen VE, Greenberger BA, Taylor JM, Edelman MJ, Lu B. “The underappreciated role of the humoral immune system and B cells in tumorigenesis and cancer therapeutics: a review.” International Journal of Radiation Oncology*Biology*Physics. 2020 Sep;108(1): 38-45. doi: 10.1016/j.ijrobp.2020.03.022
  • Chen VE, Greenberger BA, Shi Z, Gajjar S, Shi W, Mourad WF, Yan W. “Post-mastectomy and post-breast conservation surgery pain syndrome: a review of etiologies, risk prediction, and trends in management.” Translational Cancer Research. 2020 Jan;9(S1): S77-S85. doi: 10.21037/tcr.2019.06.46
  • Greenberger BA, Taylor JM, Chen VE, Den RB. “Comparing radiotherapy to prostatectomy for high-risk prostate cancer: a narrative review of mortality and quality of life outcomes.” The Cancer Journal. 2020 Jan;26(1): 29-37. doi: 10.1097/PPO.0000000000000420
  • Greenberger BA, Chen VE, Den RB. “Combined modality therapies for high-risk prostate cancer: narrative review of current understanding and new directions.” Frontiers in Oncology – Genitourinary Oncology. 2019 Nov;9: 1273. doi: 10.3389/fonc.2019.01273
  • Chen VE, Greenberger BA, Taylor JM, Lu B. “Key immune system markers in immunotherapy: absolute lymphocyte count, neutrophil to lymphocyte ratio, and alternative immune system metrics.” Therapeutic Radiology and Oncology. 2019 Sep;3(33). doi: 10.21037/tro.2019.09.01
  • Chen VE, Gillespie EF, Manger RP, Skerritt LA, Tran JH, Proudfoot JA, Sherer MV, Einck JP, Mell LK, Moore KL, Yashar CM. “The impact of daily bladder filling on small bowel dose for intensity modulated radiation therapy for cervical cancer.” Medical Dosimetry. 2019 Jun;44(2): 102-6. doi: 10.1016/j.meddos.2018.02.010
  • Chen VE, Gillespie EF, Zakeri K, Murphy JD, Yashar CM, Lu S, Einck JP. “Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer.” Advances in Radiation Oncology. 2017 Apr;2(2): 105-9. doi: 10.1016/j.adro.2017.01.012
Other Activities: 
  • Member, American Society for Radiation Oncology (ASTRO)
  • Member, American Board of Radiology (ABR)
  • Member, American Society of Clinical Oncology (ASCO)
  • Member, American College of Radiation Oncology (ACRO)
  • Member, Delta Omega Honorary Society in Public Health
  • Member, American Brachytherapy Society (ABS)
  • Member, Radiological Society of North America (RSNA)
  • Member, American Roentgen Ray Society (ARRS)